American International Group Inc. trimmed its holdings in Hill-Rom Holdings, Inc. (NYSE:HRC) by 2.8% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 132,493 shares of the medical technology company’s stock after selling 3,864 shares during the quarter. American International Group Inc. owned 0.20% of Hill-Rom worth $11,527,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. We Are One Seven LLC bought a new stake in Hill-Rom during the 4th quarter valued at $188,000. Campbell & CO Investment Adviser LLC bought a new stake in Hill-Rom during the 1st quarter valued at $203,000. CAPROCK Group Inc. bought a new stake in Hill-Rom during the 4th quarter valued at $211,000. Braun Stacey Associates Inc. bought a new stake in Hill-Rom during the 4th quarter valued at $233,000. Finally, BancorpSouth Bank bought a new stake in Hill-Rom during the 4th quarter valued at $241,000. Institutional investors own 84.49% of the company’s stock.
Shares of Hill-Rom stock opened at $89.78 on Friday. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 1.34. The firm has a market cap of $5.81 billion, a price-to-earnings ratio of 23.26, a P/E/G ratio of 1.34 and a beta of 0.98. Hill-Rom Holdings, Inc. has a 12-month low of $87.60 and a 12-month high of $89.61.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 29th. Shareholders of record on Friday, June 22nd will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a yield of 0.89%. The ex-dividend date is Thursday, June 21st. Hill-Rom’s payout ratio is currently 20.73%.
A number of equities research analysts recently commented on HRC shares. Zacks Investment Research upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $96.00 price target for the company in a report on Thursday, April 5th. Goldman Sachs started coverage on shares of Hill-Rom in a report on Wednesday, April 4th. They set a “neutral” rating and a $85.00 price target for the company. KeyCorp reiterated a “buy” rating and set a $97.00 price target on shares of Hill-Rom in a report on Thursday, January 18th. ValuEngine upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating in a report on Friday, March 2nd. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Hill-Rom in a report on Friday, January 26th. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Hill-Rom has a consensus rating of “Buy” and a consensus price target of $94.00.
In other Hill-Rom news, SVP Deborah Rasin sold 7,590 shares of the business’s stock in a transaction on Thursday, April 12th. The shares were sold at an average price of $86.02, for a total transaction of $652,891.80. Following the transaction, the senior vice president now directly owns 14,028 shares of the company’s stock, valued at approximately $1,206,688.56. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 1.90% of the stock is currently owned by insiders.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It provides medical surgical beds, intensive care unit beds, bariatric patient beds, lifts and other devices, non-invasive therapeutic products and surfaces, and communications technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.